Pfizer Inc was BioNTech SE’s largest revenue line in fiscal 2025, bringing in $1.60B of $2.87B (56%).
| Major customers [axis] | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Share Of Collaboration Partners' Gross Profit & Sales Milestones | — | — | — | — | ||||
| Pfizer Inc | $13.80B | $3.29B | $2.01B | $1.60B | ||||
| Direct Product Sales To Customers | — | — | — | — | ||||
| German Federal Ministry Of Health | $3.02B | $473.60M | $701.00M | $627.50M | ||||
| Bristol-Myers Squibb | — | — | — | $613.00M | ||||
| Sales To Collaboration Partners | — | — | — | — | ||||
| Share Of Collaboration Partners' Sales Milestones | — | — | — | — | ||||
| Covid-19 Vaccine Revenues | — | — | — | — | ||||
| Other Customers | $494.30M | $52.40M | $38.40M | $27.40M | ||||
| Genentech Inc | — | — | — | — | ||||
| Other Sales | — | — | — | — | ||||
| Other | — | — | — | — | ||||
| Total | $17.31B | $3.82B | $2.75B | $2.87B |
BioNTech SE brought in $2.87B from its four revenue lines in fiscal 2025, the year ended December 31, 2025. BioNTech SE regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $2.75B. Pfizer Inc was the largest at $1.60B (55.8%), ahead of German Federal Ministry Of Health at $627.50M (21.9%) and Bristol-Myers Squibb at $613.00M (21.4%). The remaining revenue line, Other Customers, brought in $27.40M.
Compared with fiscal 2024, German Federal Ministry Of Health fell 10.5% to $627.50M and Pfizer Inc fell 20.4% to $1.60B.
BioNTech SE began breaking out Bristol-Myers Squibb in fiscal 2025, when it brought in $613.00M.
Covid-19 Vaccine Revenues was BioNTech SE’s largest product and service line in fiscal 2025, bringing in $2.00B of $2.87B (70%).
| Product and Service | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Commercial Revenues | — | — | — | — | |||
| Covid-19 Vaccine Revenues | $17.15B | $3.78B | $2.43B | $2.00B | |||
| Revenues From Out-Licensing | — | — | — | $613.00M | |||
| Other Revenues | $165.40M | $42.80M | $319.00M | $261.60M | |||
| Research & Development Revenues | — | — | — | — | |||
| Total | $17.31B | $3.82B | $2.75B | $2.87B |
BioNTech SE brought in $2.87B from its three product and service lines in fiscal 2025, the year ended December 31, 2025. BioNTech SE regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $2.75B. Covid-19 Vaccine Revenues was the largest at $2.00B (69.5%), ahead of Revenues From Out-Licensing at $613.00M (21.4%) and Other Revenues at $261.60M (9.1%).
Compared with fiscal 2024, Covid-19 Vaccine Revenues fell 18.0% to $2.00B and Other Revenues fell 18.0% to $261.60M.
BioNTech SE began breaking out Revenues From Out-Licensing in fiscal 2025, when it brought in $613.00M.
United States was BioNTech SE’s largest region in fiscal 2025, bringing in $1.79B of $2.87B (63%).
| Geography | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| United States | $12.71B | $3.01B | $1.85B | $1.79B |
| Germany | $3.03B | $482.70M | $706.90M | $759.10M |
| Rest Of The World | $1.57B | $121.60M | $18.60M | $11.10M |
| Ireland | — | $203.80M | $177.80M | $304.80M |
| Total | $17.31B | $3.82B | $2.75B | $2.87B |
BioNTech SE brought in $2.87B from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 4.3% from $2.75B in fiscal 2024. United States was the largest at $1.79B (62.5%), ahead of Germany at $759.10M (26.5%) and Ireland at $304.80M (10.6%). The remaining region, Rest Of The World, brought in $11.10M.
Compared with fiscal 2024, Ireland grew fastest, up 71.4% to $304.80M, while United States fell the most, down 2.9% to $1.79B.
BioNTech SE began breaking out Ireland in fiscal 2023, when it brought in $203.80M.
BioNTech SE (BNTX) reports its revenue by major customers [axis], by product and service and by geography. In fiscal 2025, Pfizer Inc was its largest revenue line, bringing in $1.60B (55.8% of the total), followed by German Federal Ministry Of Health at $627.50M (21.9%).
Pfizer Inc was BioNTech SE's largest revenue line in fiscal 2025, bringing in $1.60B, or 55.8% of the $2.87B total across its four revenue lines.
Covid-19 Vaccine Revenues was BioNTech SE's largest product and service line in fiscal 2025, bringing in $2.00B, or 69.5% of the $2.87B total across its three product and service lines.
United States was BioNTech SE's largest region in fiscal 2025, bringing in $1.79B, or 62.5% of the $2.87B total across its four regions.
Among BioNTech SE's regions that make up at least 2% of revenue, Ireland grew fastest in fiscal 2025, up 71.4% from $177.80M to $304.80M.
Every figure comes from BioNTech SE's annual financial filings, as reported. Each line keeps the name BioNTech SE gives it, and years follow its fiscal calendar.
BioNTech SE's revenue by major customers [axis] goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.